Search Result

Results for "

FXa inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor Xa (32) Drug Metabolite (1) Ser/Thr Protease (1) Thrombin (8)
By Research Areas:	Cancer (7) Cardiovascular Disease (30) Inflammation/Immunology (2) Metabolic Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: Factor Xa

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-76971

Dechloro Rivaroxaban	Factor Xa	Cardiovascular Disease
Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a K_i of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC₅₀s of 2.1 nM and 92 nM, respectively .

HY-70035

Otamixaban 1 Publications Verification FXV673	Factor Xa	Cardiovascular Disease
Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.

HY-50903

Rivaroxaban Maximum Cited Publications 14 Publications Verification BAY 59-7939	Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-76948

5-R-Rivaroxaban	Factor Xa	Cardiovascular Disease
5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM).

HY-10722

DX-9065a	Factor Xa	Cardiovascular Disease
DX-9065a is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a K_i of 41 nM for human FXa. DX-9065a has low activity against other serine proteases. DX-9065a has strong anticoagulant actions .

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-10758

FXa-IN-1	Factor Xa	Cardiovascular Disease
FXa-IN-1 is a *FXa* inhibitor (IC₅₀: 3 nM, K_i: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .

HY-118803

AS1468240	Factor Xa	Others
AS1468240 is an orally active inhibitor for anticoagulant factor Xa (fXa), that inhibits human fXa with IC₅₀ of 8.7 nM. AS1468240 prolongs the coagulation time in mice .

HY-76409

Otamixaban hydrochloride FXV673 hydrochloride	Factor Xa	Inflammation/Immunology
Otamixaban (FXV673) is a potent, selective, rapid-acting, competitive, and reversible *fXa* inhibitor (K_i=0.5 nM) that effectively inhibits both free and prothrombinase-bound fXa .

HY-123356

EMD-503982	Factor Xa	Cardiovascular Disease
EMD-503982 is an orally available *FXa* inhibitor.

HY-50903S

Rivaroxaban-d4 1 Publications Verification BAY 59-7939-d₄	Factor Xa	Cardiovascular Disease
Rivaroxaban-d₄ is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].

HY-10594

Letaxaban TAK-442	Factor Xa	Cardiovascular Disease Inflammation/Immunology
Letaxaban (TAK-442) is an orally active and selective direct *FXa* inhibitor. Letaxaban is a drug with dual anticoagulant and anti-inflammatory activity that works by directly inhibiting *FXa* and by intervening in the PAR1 signaling pathway. Letaxaban can be used in the study of thrombotic diseases, cardiovascular diseases and inflammation-related diseases .

HY-50903R

Rivaroxaban (Standard)	Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (Standard) is the analytical standard of Rivaroxaban. This product is intended for research and analytical applications. Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-134686

Edoxaban impurity 4	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K_is of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .

HY-134685

Edoxaban impurity 6	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban impurity 6 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K_is of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .

HY-10264S

Edoxaban-d6 DU-176-d₆	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-10268S

Betrixaban-d6	Factor Xa	Cardiovascular Disease
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].

HY-76948R

5-R-Rivaroxaban (Standard)	Factor Xa	Cardiovascular Disease
5-R-Rivaroxaban (Standard) is the analytical standard of 5-R-Rivaroxaban. This product is intended for research and analytical applications. 5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).

HY-10267

Eribaxaban PD-0348292	Factor Xa	Cardiovascular Disease
Eribaxaban (PD-0348292) is an orally active and selective *FXa* inhibitor with a K_i value of 0.32 nM. Eribaxaban reduces thrombus formation .

HY-10264

Edoxaban 5+ Cited Publications DU-176	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human *FXa* and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-10264B

Edoxaban tosylate monohydrate 5+ Cited Publications DU-176b monohydrate	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human *FXa* and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-10264A

Edoxaban tosylate 5+ Cited Publications DU-176b	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human *FXa* and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .

HY-10264C

Edoxaban hydrochloride DU-176 hydrochloride	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human *FXa* and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .

HY-10268

Betrixaban 4 Publications Verification PRT054021	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-100652A

O-Desmethyl apixaban sulfate sodium	Factor Xa	Cardiovascular Disease
O-Desmethyl apixaban sulfate sodium is a major circulating metabolite of Apixaban in humans. O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a K_i of 58 μM .

HY-10268B

Betrixaban hydrochloride PRT054021 hydrochloride	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .

HY-10268A

Betrixaban maleate PRT054021 maleate	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban maleate shows antithrombotic effect .

HY-10264R

Edoxaban (Standard)	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human *FXa* and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-10281

YM-60828 methanesulfonate	Factor Xa	Cardiovascular Disease
YM-60828 is an *FXa* inhibitor with antithrombotic properties. In the rat arteriovenous shunt model, YM-60828 does not prolong coagulation time but reduces the levels of thrombin-antithrombin III complex (TAT) in a dose-dependent manner. YM-60828 exhibits only anti-FXa activity and does not show anti-thrombin activity, indicating that its antithrombotic effect is independent of thrombin. Therefore, the antithrombotic effect of YM-60828 can be monitored by TAT .

HY-119124

Edoxaban M4 D21-2393	Drug Metabolite	Metabolic Disease
Edoxaban M4, an active metabolite of Edoxaban, shows reproducible, but concentration-dependent matrix effects. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor .

HY-10269

LY-517717	Factor Xa	Cardiovascular Disease
LY-517717 is a potent and orally active *FXa* inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement .

HY-P99283

Concizumab NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody	Factor Xa Others	Others
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the *FXa* active site. Concizumab can be used in the study of haemophilia .

HY-14853

Darexaban YM150	Factor Xa Ser/Thr Protease	Cardiovascular Disease
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC₅₀ of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .

HY-163347

FXIIa-IN-3	Others	Cardiovascular Disease
FXIIa-IN-3 (Compound 8) is a potent and selective Factor XIIa (FXIIa) inhibitor, with an IC₅₀ of 0.045 μM. FXIIa-IN-3 also exhibits a substantial margin of selectivity against related serine proteases, including FXIa, FXa, and FIXa. FXIIa-IN-3 can be used for the research of thromboembolic diseases .

Cat. No.	Product Name	Target	Research Area

HY-P99283

Concizumab NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody	Factor Xa Inhibitory Antibodies	Others
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the *FXa* active site. Concizumab can be used in the study of haemophilia .

Cat. No.	Product Name	Chemical Structure

HY-50903S

Rivaroxaban-d4 1 Publications Verification
Rivaroxaban-d₄ is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].

HY-10264S

Edoxaban-d6
Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

Edoxaban-d6

Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-10268S

Betrixaban-d6
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: